Gastroenteropancreatic Neuroendocrine Tumors Recruiting Phase 0 Trials for Edotreotide (DB17969)

Back to Gastroenteropancreatic Neuroendocrine Tumors

Also known as: Gastro-entero-pancreatic Neuroendocrine Tumor / Gastro-entero Pancreatic Neuroendocrine Tumors / Gastro Entero Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) / Neuroendocrine Gastroenteropancreatic Tumour / Gastro-entero-pancreatic Neuroendocrine Tumors / GEP-NET / Gastro-enteropancreatic Neuroendocrine Tumor / Gastro-Entero-Pancreatic Tumors (GEPs) / Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) / Neuroendocrine Tumors,Gastroenteropancreatic / Gastroenteral-Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic Neuroendocrine Tumours / Gastroenteropancreatic Neuroendocrine Tumor / Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) / Gastroenteropancreatic Neuroendocrine Tumor Disease / Gep Net / Gastroenteropancreatic neuroendocrine tumour disease

Indication	Status	Phase
DBCOND0063370 (Gastroenteropancreatic Neuroendocrine Tumors)	Recruiting	0

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT05359146	Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)	Basic Science	Edotreotide (DB17969) Lutetium Lu-177 (DB13982)